Brief: Infinity Pharmaceuticals Expects Net Loss For 2019 To Range From $40 Mln To $50 Mln
30/07/2019 12:49
July 30 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* Q2 LOSS PER SHARE $0.18
* Q2 EARNINGS PER SHARE ESTIMATE $-0.07 -- REFINITIV IBES
DATA
* EXPECTS NET LOSS FOR 2019 TO RANGE FROM $40 MILLION TO $50
MILLION.
* INITIATING MARIO-3 PHASE 2 STUDY IN FRONT-LINE TRIPLE
NEGATIVE
BREAST AND RENAL CELL CANCER IN 3Q
* INFINITY PHARMACEUTICALS - SEES 2019 -END CASH, CASH
EQUIVALENTS& AVAILABLE-FOR-SALE SECURITIES BALANCE RANGING FROM
$40 MILLION TO $50 MILLION.
* INFINITY PHARMACEUTICALS - SEES EXISTING CASH, CASH
EQUIVALENTS
& AVAILABLE-FOR-SALE SECURITIES WILL BE ADEQUATE TO SATISFY
CAPITAL NEEDS INTO H2 2020
Source text for Eikon: ID:nPnZQD6Ja
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX